InvestSMART

Dimerix Limited (ASX:DXB)

ALERT: Price-sensitive ASX Announcement for DXB
Current share price for DXB : $0.260 0.095 (57.58%)+
Announcement
Release
16 Jun 2026 10:20AM
Price at Release
$0.165
Full Release
download
Summary
Dimerix Limited has entered into an exclusive license agreement with Everest Medicines for the commercialization of its Phase 3 drug candidate DMX-200 for all indications, including Focal Segmental Glomerulosclerosis (FSGS), in Greater China, South Korea, and certain Southeast Asian countries. The agreement allows Dimerix to receive an upfront payment of US$10 million and potential success-based milestone payments up to US$330 million. Additionally, Dimerix will receive tiered royalties on net sales. Everest will leverage its specialty kidney disease expertise to commercialize DMX-200, while Dimerix retains rights in all other territories. The ACTION3 Phase 3 clinical trial for DMX-200 is fully recruited, and initial results suggest it performs better than placebo in reducing proteinuria. The collaboration aims to expand the reach of DMX-200 to a significant patient population in need of treatment options.
Key Points
  • Exclusive license agreement with Everest Medicines for DMX-200.
  • Commercialization rights in Greater China, South Korea, and Southeast Asia.
  • Dimerix receives US$10 million upfront payment and potential US$330 million in milestone payments.
  • Tiered royalties on DMX-200 net sales ranging from 10-15%.
  • ACTION3 Phase 3 trial shows promising interim results for FSGS.
  • Everest to handle regulatory and commercialization activities in licensed territories.
  • Dimerix retains rights to unlicensed territories outside the agreement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.